

June 30, 2017

## Nippon Shokubai announces to Form a Capital Alliance with Rena Therapeutics

NIPPON SHOKUBAI CO., LTD. (Headquarter: Osaka, Japan, President: Yujiro Goto, hereinafter “Nippon Shokubai”) announces that Nippon Shokubai has decided to subscribe for shares of Rena Therapeutics Inc. (Headquarter: Tokyo, Japan, President: Jun Sasaki, hereinafter “Rena Therapeutics”) through a third party allotment, and today completed payment procedures.


### 1. Purpose of the Alliance

In the current long-term business plan “Reborn Nippon Shokubai 2020” started in 2014 and the 2<sup>nd</sup> medium-term Business Plan “Reborn Nippon Shokubai 2020 NEXT” started in 2017, Nippon Shokubai has a plan to open up a health and medical business field as one of the new business domains. Nippon Shokubai is establishing a drug development support business that provides customers a consistent service from drug discovery & clinical studies to contract manufacturing.

Nippon Shokubai is targeting nucleic-acid drugs as a next category, in addition to peptide drugs and DDS category. Nippon Shokubai keeps on seeking out chances of business partnerships with those who have innovative seeds in these fields.

Rena Therapeutics aims to develop the Hetero Duplex Oligonucleotide(HDO) technology invented by Professor Takanori Yokota of Tokyo Medical and Dental University and Professor Satoshi Obika of Osaka University et al. to be a platform applicable to drug discovery and development ,and expedite making nucleic-acid drugs practical.

Nucleic-acid drugs has been gathering attention as the next generation drug for treating intractable diseases, however, various issues have been revealed and widely known: instability in blood and side-effects. The Hetero Duplex Oligonucleotide (HDO) technology is to utilize double stranded DNA/RNA with ligand molecules for proper drug delivery (Figure1), and it is highly expected to overcome these issues.



“Figure1” by courtesy of Rena Therapeutics Inc.

Nippon Shokubai will support the development of HDO technology through this capital alliance and will jointly consider the possibility of business collaboration with respect to development and manufacturing based on HDO technology.

## 2. Outline of the Alliance

Class and numbers of shares to be subscribed : 125,000 shares of Class B preferred stock  
Share-holding after subscription : 26.79% of all issued stocks (Voting stocks)  
Payment date : June 30th, 2017

## 3. Outline of Rena Therapeutics

|                               |  |
|-------------------------------|--|
| Name                          | Rena Therapeutics Inc.   |
| Head Office                   | Tokyo Medical and Dental University Building 22,2-3-10<br>Kandasurugadai, Chiyoda-ku, Tokyo, Japan |
| Representative                | Jun Sasaki   |
| Activity                      | Business of platform technology for drug discovery and development                                 |
| Capital                       | 330 million yen  |
| Established                   | January 15th, 2015   |
| Numbers of shares outstanding | 316,666 shares (All stocks with voting right)  |
| End of fiscal year            | December 31 <sup>st</sup>  |
| Employees                     | 8 (as of June 2017)  |
| Website                       | <a href="http://www.renatherapeutics.com/">http://www.renatherapeutics.com/</a>                    |

## 4. Forecast

Nippon Shokubai will consider further possibility of business collaboration with Rena Therapeutics. Additionally, Nippon Shokubai will keep on seeking out of the possibility of further partnerships in order to construct a drug development support business.

---

**【Contacts】** Investor & Public Relations Dept.  
NIPPON SHOKUBAI CO., LTD.  
TEL: +81-3-3506-7605 E-mail: [shokubai@n.shokubai.co.jp](mailto:shokubai@n.shokubai.co.jp)